Peptide Therapeutics intermediate
Milestone 014: Oligopeptide Research Reference
2017: Semaglutide (Ozempic) approved for type 2 diabetes. Once-weekly GLP-1 agonist. This peptide or oligopeptide is studied for its biological activity, str...
By Encyclopeptide Editorial | 1 min read
milestone-014 peptide research
Overview
2017: Semaglutide (Ozempic) approved for type 2 diabetes. Once-weekly GLP-1 agonist.
Clinical Significance
This topic has important implications for peptide research and clinical applications.
References
- Encyclopeptide Database. “Milestone 014” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Milestone 014: Oligopeptide Research Reference with interactive quizzes on Wikipept.
Take a Quiz on Wikipept